Login or register (free and only takes a few minutes) to participate in this question.
You will also have access to many other tools and opportunities designed for those who have language-related jobs (or are passionate about them). Participation is free and the site has a strict confidentiality policy.
Explanation: Tratamiento sistémico adyuvante del cáncer de mama
Vicente Valero, M.D., Edgardo Rivera, M.D., Gabriel Hortobagyi, M.D
Departamento de Oncología Médica, Mama y Ginecología
División de Medicina
The University of Texas
M. D. Anderson Cancer Center
Adjuvant Systemic Therapy of Breast Cancer SUMMARY: Breast cancer is a major public health problem throughout the industrialized countries. It is also becoming a substantial problem in the developing countries. Breast cancer is one of the leading causes of death in women in the United States. In spite of the fact than 90% of the patients are diagnosed at early stages of the disease, more that 50% will eventually die of this disease. Over the last two decades, significant advances in the treatment in breast cancer with systemic adjuvant therapies have taken place. Because of the high incidence of breast cancer, these advances in the efficacy of treatment in breast cancer represent thousands of lives saved every year. This article summarizes the current status and controversies of adjuvant systemic therapy of breast cancer.
La quimioterapia neoadyuvante puede definirse como un tratamiento sistémico dado cuanto antes, una vez que se ha hecho el diagnóstico de cáncer y antes de que se realice la terapia locorregional definitiva. La meta principal de la neoadyuvancia es reducir lo más posible un tumor avanzado, haciéndolo quirúrgico y/o sujeto a tratamiento definitivo por radioterapia. http://users.rcn.com/icps/Medico/MEDICO96/July/Hunis.html